- Home
- LPRO vs TYRA Comparison
LPRO vs TYRA Comparison
Compare LPRO & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPRO
- TYRA
- Stock Information
- Founded
- LPRO 2000
- TYRA 2018
- Country
- LPRO United States
- TYRA United States
- Employees
- LPRO N/A
- TYRA N/A
- Industry
- LPRO Finance: Consumer Services
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- LPRO Finance
- TYRA Health Care
- Exchange
- LPRO Nasdaq
- TYRA Nasdaq
- Market Cap
- LPRO 751.9M
- TYRA 871.8M
- IPO Year
- LPRO N/A
- TYRA 2021
- Fundamental
- Price
- LPRO $6.27
- TYRA $15.39
- Analyst Decision
- LPRO Buy
- TYRA Strong Buy
- Analyst Count
- LPRO 7
- TYRA 5
- Target Price
- LPRO $6.80
- TYRA $31.00
- AVG Volume (30 Days)
- LPRO 427.7K
- TYRA 625.3K
- Earning Date
- LPRO 11-07-2024
- TYRA 11-07-2024
- Dividend Yield
- LPRO N/A
- TYRA N/A
- EPS Growth
- LPRO N/A
- TYRA N/A
- EPS
- LPRO 0.04
- TYRA N/A
- Revenue
- LPRO $95,887,000.00
- TYRA N/A
- Revenue This Year
- LPRO N/A
- TYRA N/A
- Revenue Next Year
- LPRO $15.00
- TYRA N/A
- P/E Ratio
- LPRO $164.12
- TYRA N/A
- Revenue Growth
- LPRO N/A
- TYRA N/A
- 52 Week Low
- LPRO $4.57
- TYRA $10.60
- 52 Week High
- LPRO $8.70
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- LPRO 54.27
- TYRA 32.20
- Support Level
- LPRO $6.13
- TYRA $15.74
- Resistance Level
- LPRO $6.80
- TYRA $16.68
- Average True Range (ATR)
- LPRO 0.37
- TYRA 1.30
- MACD
- LPRO 0.04
- TYRA -0.21
- Stochastic Oscillator
- LPRO 60.12
- TYRA 6.42
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against losses from defaults.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).